Saito Takeshi, Reyna Rachel A, Taniguchi Satoshi, Littlefield Kirsten, Paessler Slobodan, Maruyama Junki
Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Department of Microbiology & Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Vaccines (Basel). 2023 Mar 13;11(3):635. doi: 10.3390/vaccines11030635.
The viral family contains several members that cause severe, and often lethal, diseases in humans. Several highly pathogenic arenaviruses are classified as Risk Group 4 agents and must be handled in the highest biological containment facility, biosafety level-4 (BSL-4). Vaccines and treatments are very limited for these pathogens. The development of vaccines is crucial for the establishment of countermeasures against highly pathogenic arenavirus infections. While several vaccine candidates have been investigated, there are currently no approved vaccines for arenavirus infection except for Candid#1, a live-attenuated Junin virus vaccine only licensed in Argentina. Current platforms under investigation for use include live-attenuated vaccines, recombinant virus-based vaccines, and recombinant proteins. We summarize here the recent updates of vaccine candidates against arenavirus infections.
该病毒家族包含几个可在人类中引发严重且往往致命疾病的成员。几种高致病性沙粒病毒被归类为风险等级4的病原体，必须在最高生物安全防护设施——生物安全4级（BSL-4）实验室中进行处理。针对这些病原体的疫苗和治疗方法非常有限。疫苗的研发对于建立针对高致病性沙粒病毒感染的应对措施至关重要。虽然已经对几种候选疫苗进行了研究，但目前除了仅在阿根廷获得许可的减毒活疫苗株“Candid#1”（一种朱宁病毒减毒活疫苗）外，尚无已获批的沙粒病毒感染疫苗。目前正在研究的疫苗平台包括减毒活疫苗、基于重组病毒的疫苗和重组蛋白。我们在此总结了针对沙粒病毒感染的候选疫苗的最新进展。
Zotero 插件
